Evidence map›Paper›PMID 38319461›Full record

ArticleAIDS and behavior2024

Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border Metroplex.

William H Eger, Angela R Bazzi, Chad J Valasek, Carlos F Vera, Alicia Harvey-Vera, Irina Artamonova, M Gudelia Rangel, Steffanie A Strathdee, Heather A Pines

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William H EgerSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
Angela R BazziHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA.
Chad J ValasekSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
Carlos F VeraSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
Alicia Harvey-VeraSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
Irina ArtamonovaSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
M Gudelia RangelMexico Section of the US-Mexico Border Health Commission, Tijuana, Baja California, Mexico.
Steffanie A StrathdeeSchool of Medicine, University of California, San Diego, La Jolla, CA, USA.
Heather A PinesSchool of Medicine, University of California, San Diego, La Jolla, CA, USA. hpines@sdsu.edu.ORCID http://orcid.org/0000-0002-7173-1981

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
NIAID NIH HHS P30 AI036214NIDA NIH HHS K01 DA043412NIDA NIH HHS K01DA043412NIDA NIH HHS R01 DA049644NIDA NIH HHS R01DA049644NIDA NIH HHS T32 DA023356NIDA NIH HHS T32DA023356
6 · The paper itself

Abstract

Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) could help overcome multilevel challenges to HIV prevention for people who inject drugs (PWID), including those in the binational San Diego-Tijuana metroplex. Yet, general PrEP awareness and interest in LAI-PrEP remain underexplored among PWID. From 2020 to 2021, 562 HIV-negative PWID in San Diego and Tijuana completed surveys assessing general PrEP awareness and interest in oral and LAI-PrEP. Modified Poisson regression examined factors associated with general PrEP awareness. Multinomial logistic regression assessed factors associated with interest in both oral and LAI-PrEP, oral PrEP only, LAI-PrEP only, or neither. General PrEP awareness was low (18%) and associated with experiencing unsheltered homelessness (adjusted prevalence ratio [APR] = 1.50, 95% confidence interval [CI]: 0.96-2.33), past 6-month fentanyl injection (APR = 1.53, 95% CI: 1.04-2.25), and transactional sex (APR = 1.71, 95% CI: 1.06-2.76). Interest in oral PrEP only was most common (44%), followed by LAI-PrEP only (25%) and neither (16%). Compared to the odds of being interested in LAI-PrEP only, the odds of being interested in oral PrEP only were lower among those who were stopped by police (AOR = 0.38, 95% CI: 0.22-0.65), reported past 6-month fentanyl injection (AOR = 0.33, 95% CI: 0.20-0.56), polydrug use (AOR = 0.48, 95% CI: 0.27-0.86), injecting multiple times daily (AOR = 0.26, 95% CI: 0.14-0.46), receptive syringe use (AOR = 0.30, 95% CI: 0.19-0.49), and higher perceived HIV risk (AOR = 0.24, 95% CI: 0.15-0.39). Interest in LAI-PrEP was more common among PWID reporting social and structural factors that could interfere with oral PrEP adherence, suggesting LAI-PrEP implementation could increase PrEP coverage among those most vulnerable to HIV.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSubstance Abuse, IntravenousAdultCaliforniaDelayed-Action PreparationsFemaleHealth Knowledge, Attitudes, PracticeHumansIll-Housed PersonsMaleMiddle AgedSurveys and QuestionnairesAnti-HIV AgentsDelayed-Action PreparationsHIV preventionInjection drug usePeople who inject drugsPre-exposure prophylaxis

Identifiers

PMID38319461
PMCPMC11549966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.